Coagulation Factor V Activity Assay, Plasma
Coagulation factor V (FV), also known as proaccelerin, is a protein that serves as an essential cofactor in the prothrombinase enzyme complex which converts prothrombin to thrombin. FV also serves as an important modulator in the early phase of blood clotting as it contributes to the anticoagulant pathway by inhibiting factor VIII activity. Therefore, deficiency in FV activity might contribute to both bleeding and thrombosis. Factor V is a vitamin K-independent protein synthesized in the liver, endothelium and platelets. Factor V is highly susceptible to proteolytic inactivation, which often can impact the assay results, which is why FV is also known as labile factor. The most common abnormal tests associated with deficiency of factor V is prolonged prothrombin time and activated partial thromboplastin time, which can be an indicator of a propensity for bleeding.
Congenital Factor V deficiency is a very rare blood clotting disorder with mild to severe hemorrhagic symptoms (prolonged blood clotting after an injury or surgery) caused by a mutation in factor V, also known as Factor V Leiden, with a prevalence in the general population of 1 in 1,000,000 in the homozygous form. Heterozygous carriers have approximately half-normal levels of FV and are usually asymptomatic. The homozygous mutation will lead to significantly decreased levels and function of FV in plasma.
- As an aid in diagnosis of Congenital Factor V deficiency
- Evaluation of thrombotic risk and venous thromboembolism
- As an aid in diagnosis of pulmonary embolism and coronary artery disease, and/or stroke
- Evaluation for other thrombolytic problems
- Investigation of prolonged prothrombin time or activated partial thromboplastin time
Decreased in congenital disorders (rare):
- Inherited autosomal deficiency
- Bleeding in homozygotes
Decreased acquired causes:
- Liver disease
- Pathological fibrinolysis
- Disseminated intravascular coagulation (DIC)
Acquired deficiencies are much more common than congenital.
Congenitally deficient homozygotes generally have levels < or =10% to 20%.
Congenitally deficient heterozygotes generally have levels < or =50%.
Congenital deficiency may occur in combined association with factor VIII deficiency.
Adults: 70-165%
Normal, full-term newborn infants may have borderline low or mildly decreased levels (30% to 35%) which reach adult levels within 21 days postnatal. Healthy premature infants (30-36 weeks gestation) may have borderline low or mildly decreased levels.
Prothrombin Clot-Based Assay.
Plasma (citrated plasma, blue topped tube).
Stability
- Ambient: 4 hours
- Refrigerated: Unacceptable
- Frozen: 3 months
- Semin Thromb Hemost. 2009 Jun;35(4):382-389. [PMID: 19598066]
- Int J Hematol. 2009 Jan;89(1):71-5. [PMID: 19052695]
- Semin Thromb Hemost. 2009 Jun;35(4):390-9. [PMID: 19598067]
- Blood Coagul Fibrinolysis. 2011;22(3):160-166. [PMID: 21245750]
- Vitam Horm. 2008;78:281-374. [PMID: 18374200]